EEDQ reduces the striatal neurotensin mRNA response to haloperidol

Monique R. Adams, Dorcas J. Dobie, Kalpana M. Merchant, Alan Unis, Daniel M. Dorsa

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Haloperidol is believed to induce neurotensin/neuromedin N (NT/N) gene expression in the dorsolateral striatum (DLST) of the rat brain via dopamine D2 receptor blockade, but is also known to interact with other receptors as well. To further characterize haloperidol's effects, rats were treated with the irreversible monoaminergic receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2 hydroxyquinolone (EEDQ). In situ hybridization was performed for NT/N mRNA. D2-like and sigma receptor autoradiography was performed using 125I-sulpride and 3H-1,3-di-o-tolylguanidine (DTG), respectively. Despite antagonism of D2 receptors, pretreatment with EEDQ failed to significantly reduce the NT/N mRNA response when given 3 days prior to the haloperidol challenge. These data suggest that the acute effects of haloperidol on NT/N mRNA expression in large part result from D2 receptor antagonism. Nonetheless, a contribution of other receptors can not be excluded.

Original languageEnglish (US)
Pages (from-to)527-535
Number of pages9
Issue number4
StatePublished - 1997
Externally publishedYes


  • Antipsychotic
  • Dopamine
  • Dorsolateral striatum
  • Drugs Haloperidol
  • EEDQ
  • Neurotensin/neuromedin N

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Endocrinology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'EEDQ reduces the striatal neurotensin mRNA response to haloperidol'. Together they form a unique fingerprint.

Cite this